Pharma News: Immunomedics, Medicis, Anacor Pharmaceuticals Video

Immunomedics (IMMU) and UCB said today they have amended their development, collaboration and license agreement for developing and marketing epratuzumab for autoimmune indications. The restructuring gives UCB the flexibility to select a partner to sublicense its rights for certain territories, in exchange for returning its buy-in right for the cancer indication to Immunomedics.